|
[1] Groll A H, Shah P M, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect, 1996, 33(1): 23-32.
[2] Vogeser M, Haas A, Aust D, et al. Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis, 1997, 16(1): 1-6.
[3] Ribaud P, Chastang C, Latge J P, et al. Outcome and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis, 1999, 28: 322-330.
[4] Denning D W. Invasive aspergillosis. Clin Infect Dis, 1998, 26(4): 781-805.
[5] Moore R D, Chaisson R E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med, 1996, 124(7): 633-642.
[6] Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated penicilliummarneffei infection in southeast Asia. Lancet, 1994, 344(8915): 110-113.
[7] Douglas C. Fungal beta (1,3)-D-glucan synthesis. Med Mycol, 2001, 39 (suppl 1): 55-66.
[8] 孟国彬. 棘白霉素类抗真菌药的研究进展. 河北化工, 2011, 34(1): 40-43. Meng G B. The study progress of echinocandin antifungal agents.Hebei Chemical Industry, 2011, 34(1): 40-43.
[9] 李岷, 沈永年, 吕桂霞,等. 棘白菌素类抗真菌药. 中国真菌学杂志, 2009, 4(4): 249-256. Li M, Shen Y N, Lv G X, et al. Echinocandin antifungal agent. Chin J Mycol, 2009, 4(4): 249-256.
[10] 于会贤, 仓基勇. 棘白霉素类抗真菌药的临床应用. 医学信息, 2010, 5(4): 921. Yu H X, Cang J Y. Clinical application of echinocandin antifungal agent, Med Inform, 2010, 5(4): 921.
[11] 袁瑾懿, 杨帆. 棘白菌素类的新品种:米卡芬净. 中国感染与化疗杂志, 2007, 7(2): 111-112. Yuan J Y, Yang F. Micafungin: a new echinocandin, Chin J Infect Chemother, 2007, 7(2): 111-112.
[12] Deresinski S C, Stevens D A.Caspofungin. Clin Infect Dis, 2003, 36(1): 1145-1157.
[13] Keating G M, Figgitt D P. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs, 2003, 63(10): 2235-2263.
[14] Chandrasekar P H, Sobel J D. Micafungin: a new echinocandin. Clin Infect Dis, 2006, 42(5): 1171-1181.
[15] Vazquez J A, Sobel J D. Anidulafungin: A Novel Echinocandin. Clin Infect Dis, 2006, 42(5): 215-222.
[16] Shao L, Li J, Liu A, et al. Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains. Appl Environ Microbiol, 2013, 79(4): 1126-1133.
[17] Ueda S, Shibata T, Ito K, et al. Cloning and expression of the FR901379 acylase gene from Streptomyces sp. No. 6907. J Antibiot, 2011, 64(2): 169-175.
[18] Boeck L D, Fukuda D S, Abbott B J, et al. Deacylation of A21978C, an acidic lipopeptide antibiotic complex, by Actinoplanesutahensis. J Antibiot, 1988, 41(8): 1085-1092.
[19] Takeshima H, Inokoshi J, Takada Y, et al. A deacylation enzyme for aculeacin A, a neutral lipopeptide antibiotic, from Actinoplanesutahensis: purification and characterization. J Biochem, 1989, 105(4): 606-610.
[20] Gilbert M, Ostiguy S, Kluepfel D, et al. Cloning of a secA homolog from Streptomyces lividans 1326 and overexpression in both S.lividans and Escherichia coli. Biochim Biophys Acta, 1996, 1296(1): 9-12.
[21] Horinouchi S, Nishiyama M, Nakamura A, et al. Construction and characterization of multicopy expression-vectors in Streptomyces spp. Mol Genet Genom, 1987, 210(3):468-475.
|
